Q2 Earnings Forecast for ACXP Issued By HC Wainwright

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) – Investment analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for Acurx Pharmaceuticals in a note issued to investors on Thursday, May 15th. HC Wainwright analyst M. Keller expects that the company will post earnings per share of ($0.10) for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Acurx Pharmaceuticals’ current full-year earnings is ($0.89) per share. HC Wainwright also issued estimates for Acurx Pharmaceuticals’ Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.45) EPS, FY2026 earnings at ($0.39) EPS and FY2027 earnings at ($0.35) EPS.

Acurx Pharmaceuticals Price Performance

Acurx Pharmaceuticals stock opened at $0.39 on Monday. The stock’s 50 day moving average is $0.39 and its 200 day moving average is $0.76. The firm has a market cap of $9.09 million, a P/E ratio of -0.36 and a beta of -1.37. Acurx Pharmaceuticals has a one year low of $0.30 and a one year high of $3.33.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03.

Hedge Funds Weigh In On Acurx Pharmaceuticals

A hedge fund recently raised its stake in Acurx Pharmaceuticals stock. Prospect Financial Services LLC increased its stake in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 11.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 329,076 shares of the company’s stock after acquiring an additional 34,001 shares during the quarter. Prospect Financial Services LLC owned about 1.93% of Acurx Pharmaceuticals worth $268,000 at the end of the most recent reporting period. 11.53% of the stock is currently owned by institutional investors.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.